Navigation Links
Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Maryland's Emerging Company of the Year Award
Date:5/19/2008

ROCKVILLE, Md., May 19 /PRNewswire-USNewswire/ -- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations.

http://techcouncilmd.com/News/tcmnews_080516.html

"All the members of the Sanaria team go to work every day with only one goal in mind, to develop a vaccine that will prevent millions of deaths from malaria," said Sanaria founder and CEO, Stephen L. Hoffman. "I am honored to accept this award on their behalf, and on behalf of our partners who have invested so much in us."

The PATH Malaria Vaccine Initiative, which is partnering with Sanaria Inc. to accelerate development of the company's novel malaria vaccine candidate, welcomed the news. "We at MVI are pleased at the recognition of our partner's efforts to establish a core platform technology for producing attenuated sporozoite malaria vaccines," said Director Dr. Christian Loucq.

The annual dinner and awards celebration was attended by Maryland Governor Martin O'Malley, additional state and local government representatives, and over 900 members of the Maryland technology and biotech industries.

About Sanaria Inc., The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to the use of funds to date to complete manufacturing the vaccine, and conduct initial clinical studies. Such risks and uncertainties include, but are not limited to, the Company's ability to raise funds on reasonable terms, the regulatory approval process, competitive products, and maintenance of its patent portfolio, among others.

Media contact: Adam Richman, Sanaria Inc., 9800 Medical Center Drive, Suite A209, Rockville, MD 20850 USA

Ph: +1-301-770-3222

Fax: +1-301-770-5554

Email: arichman@sanaria.com


'/>"/>
SOURCE Sanaria Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
2. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
3. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
4. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
5. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
Breaking Medicine News(10 mins):